Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00319956 · ClinicalTrials.gov registry record · Phase 2
Trial II of Lung Protection With Azithromycin in the Preterm Infant
A Phase 2 study of Bronchopulmonary Dysplasia, sponsored by Hubert Ballard.
- Completed
- Registry status
- Phase 2
- Development phase
- 220
- Enrollment target
- 1
- Study location
NCT00319956 is a Phase 2 study of Bronchopulmonary Dysplasia that has completed, run by Hubert Ballard. The registered enrollment target is 220 participants, roughly in line with the 229-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT00319956, a Phase 2 study of Bronchopulmonary Dysplasia, has completed, sponsored by Hubert Ballard.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 220 participants
- Enrollment target
- 1
- Study location
Study Summary
The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Azithromycin
Study Locations (1)
Kentucky
- University of Kentucky Medical Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2004-09 |
| Est. Completion | 2012-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00319956
The ClinicalTrials.gov registry entry for NCT00319956 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 229-participant average among 29 other Bronchopulmonary Dysplasia trials with a reported enrollment target. The listed sponsor is Hubert Ballard, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bronchopulmonary Dysplasia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00319956 reports 1 study location spanning 1 distinct geographic area - top geographies include Kentucky.
Frequently Asked Questions
What is clinical trial NCT00319956 about?
NCT00319956 is a clinical study titled "Trial II of Lung Protection With Azithromycin in the Preterm Infant". The hypothesis of this study is that administration of azithromycin to ventilated premature infants will decrease the incidence and severity of BPD. The purpose of this study is to determine if Azithromycin treatment is beneficial for prevention of bronchopulmonary dysplasia in preterm infants.
What is the current status of trial NCT00319956?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 220 participants. The study started on 2004-09. Estimated completion is 2012-06.
What conditions does trial NCT00319956 study?
This clinical trial studies the following conditions: Bronchopulmonary Dysplasia.
What interventions are being tested in trial NCT00319956?
The interventions under investigation include: Placebo (DRUG), Azithromycin (DRUG).
Who is sponsoring clinical trial NCT00319956?
This trial is sponsored by Hubert Ballard, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00319956 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bronchopulmonary Dysplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Efficacy and Safety Study of OHB-607 in Preventing Bronchopulmonary Dysplasia in Extremely Premature Infants
RECRUITING · Phase 2
-
Vitamin D Supplementation for Extremely Preterm Infants
COMPLETED · Phase 2
-
Safety of Sildenafil in Premature Infants
COMPLETED · Phase 2
-
Safety of Furosemide in Premature Infants at Risk of Bronchopulmonary Dysplasia (BPD)
COMPLETED · Phase 2
-
Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome
COMPLETED · Phase 2
-
The Diaphragmatic Initiated Ventilatory Assist (DIVA) Trial
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.